Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What HappenedDefense World · Oct 3, 2026
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?Defense World · Oct 2, 2026
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from AnalystsDefense World · Oct 1, 2026
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli WalbertGlobeNewsWire · Sep 24, 2026
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual BleedingGlobeNewsWire · Sep 17, 2026Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.